SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO

RULE 13d-2(a)

(Amendment No. 4)*

MEDPRO SAFETY PRODUCTS, INC.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

58504M100

(CUSIP Number)

Vision Capital Advisors, LLC

20 West 55th Street, 5th Floor

New York, NY 10019

Attention: James Murray

Tel: 212.849.8237

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

November 30, 2012

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box x.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes.)

CUSIP No.: 58504M100

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Adam Benowitz

(a) ¨

(b) ¨

AF

United States

31,634,579*

74.3%*

IN

* As of December 5, 2012 (the date of filing of this Schedule 13D).

CUSIP No.: 58504M100

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Carl Kleidman

(a) ¨

(b) ¨

OO

United States

100,000*

0.8%*

IN

* As of December 5, 2012 (the date of filing of this Schedule 13D).

CUSIP No.: 58504M100

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Vision Capital Advisors, LLC

(a) ¨

(b) ¨

AF

Delaware

31,634,579*

74.3%*

IA

* As of December 5, 2012 (the date of filing of this Schedule 13D).

CUSIP No.: 58504M100

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Vision Opportunity Master Fund, Ltd.

(a) ¨

(b) ¨

WC

Cayman Islands

See Item 5

See Item 5

CO

CUSIP No.: 58504M100

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Vision Capital Advantage Fund, L.P.

(a) ¨

(b) ¨

WC

Delaware

See Item 5

See Item 5

PN

CUSIP No.: 58504M100

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

VCAF GP, LLC

(a) ¨

(b) ¨

AF

Delaware

See Item 5

See Item 5

OO

EXPLANATORY NOTE

This Amendment No. 4 to Schedule 13D (this “Amendment No. 4”) is being filed with respect to the beneficial ownership of common stock, par value $0.001 per share (the “Common Stock”), of MedPro Safety Products, Inc., a Delaware corporation (the “Company” or the “Issuer”). This Amendment No. 4 supplements Items 3 and 4, and amends and restates in its entirety Item 5, of the Schedule 13D originally filed on August 13, 2010 (as amended to date).

The funds used to acquire the securities described in Item 4 of this Amendment No. 4 were from working capital of the Master Fund, and the amount of funds totaled in the aggregate $309,000.

November 30, 2012 Drawdown of Series D Senior Secured Promissory Note

On November 30, 2012, the Issuer drew down $309,000 from the Series D Note with the Master Fund. The Master Fund received 6,953 shares of Series D Preferred Stock in connection with this drawdown (currently convertible into 115,883 shares of Common Stock).

(a) As of December 5, 2012 (the date of filing of this Schedule 13D), the Master Fund and VCAF, collectively, (i) own 1,939,769 shares of Common Stock, (ii) have the ability to acquire an additional 29,694,810 shares of Common Stock through the exercise or conversion of derivative securities and (iii) thus beneficially own 31,634,579 shares of Common Stock, representing 74.3% of all of the Issuer’s outstanding Common Stock. The Investment Manager and Mr. Benowitz (and the General Partner with respect to the shares of Common Stock owned by VCAF) may each be deemed to beneficially own the shares of Common Stock beneficially owned by the Master Fund and VCAF. Each disclaims beneficial ownership of such shares.

As of December 5, 2012 (the date of filing of this Schedule 13D), Mr. Kleidman has the ability to acquire 100,000 shares of Common Stock through the exercise or conversion of derivative securities and thus beneficially owns 100,000 shares of Common Stock, representing 0.8% of all of the Issuer’s outstanding Common Stock.

The foregoing is based on 12,871,155 shares of Common Stock outstanding as of November 12, 2012, as reported on the Issuer’s Form 10-Q for the quarterly period ended September 30, 2012, filed with the SEC on November 14, 2012.

(b) The Reporting Persons (other than Mr. Kleidman) have shared power (with each other and not with any third party), to vote or direct the vote of and to dispose or direct the disposition of the 31,634,579 shares of Common Stock reported herein.

Mr. Kleidman has sole power to vote or direct the vote of and to dispose or direct the disposition of the 100,000 shares of Common Stock reported herein.

(c) Other than as described in Item 4 (as supplemented by this Amendment No. 4), no transactions in the Common Stock have been effected by the Reporting Persons in the last sixty (60) days.

(d) Not applicable.

(e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: December 5, 2012